Professional Documents
Culture Documents
Cipla LTD PDF
Cipla LTD PDF
CIPLA LTD
EQUITY RESEARCH
INDUSTRY: PHARMACEUTICALS
Market Size
Indian pharmaceutical sector is expected to grow to US$ 100 billion and medical device
market expected to grow US$ 25 billion by 2025. Pharmaceuticals exports from India stood
at US$ 19.14 billion in FY19 and US$ 13.69 billion in FY20 (up to January 2020).
Pharmaceutical exports include bulk drugs, intermediates, drug formulations, biologicals,
Ayush & herbal products and surgicals.
Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from
the US Food and Drug Administration (USFDA) in 2017 and received a total of 415 product
approvals in 2018 and 73 tentative approvals. The country accounts for around 30 per cent
(by volume) and about 10 per cent (value) in the US$ 70-80 billion US generics market.
India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture,
bio-industry and bioinformatics is expected grow at an average growth rate of around 30 per
cent a year and reach US$ 100 billion by 2025.
India’s domestic pharmaceutical market turnover reached Rs 1.4 lakh crore (US$ 20.03
billion) in 2019, growing 9.8 per cent year-on-year (in Rs) from Rs 129,015 crore (US$ 18.12
billion) in 2018.
1
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
2
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
INTRODUCTION
HISTORY
3
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
OPERATIONS
As on 31 March 2013, the company had 22,036 employees (out of which 2,455
were women (7.30%) and 23 were employees with disabilities (0.1%)). During
the FY 2013–14, the company incurred ₹1,285 crore (equivalent to ₹17 billion
or US$230 million in 2019) on employee benefit expenses.
LISTING
The equity shares of Cipla are listed on the Bombay Stock Exchange, where it is
a constituent of the BSE SENSEX index, and the National Stock Exchange of
India, where it is a constituent of the CNX Nifty. Its Global Depository Receipts
(GDRs) are listed on the Luxembourg Stock Exchange.
As of 30 September 2014, the promoter group, Y. K. Hamied and his family
held around 36.80% equity shares in Cipla. Around 148,000 individual
shareholders held approx. 18.67% of its shares. LIC is the largest non-promoter
shareholder with approx. 6.45% shareholding in the company by the end of
September 2013.
4
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
BOARD OF DIRECTORS
5
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
CORPORATE INFORMATION
6
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
BUSINESS MODEL
• At the heart of the operations lies their business model, which determines
the way they calibrate the six capitals and transform input into outcomes
to achieve strategic goals. The business model demonstrates how they
conduct business to retain leadership position across markets.
• The OneCipla ethos and Credo, which reflect in their day-to-day business
conduct, form the bedrock of their business model and inspire the
employees to operate within the perimeter of ethics, transparency and
good governance with every step they take.
• The business model is driven by elements that are critical to Cipla and
encompasses the internal and external factors influencing the company.
7
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
PRODUCTS
CIPLA HEADQUARTERS
8
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
GEOGRAPHICAL PRESENCE
9
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
RECOMMENDATIONS
10
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
FINANCIAL DATA
11
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
BALANCE SHEET
12
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
13
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
Net Cash Flow from Operating Activity 1468.05 1116.53 2207.39 1728.40 1051.41
Net Inc/Dec In Cash and Cash Equivalent -152.98 172.85 4.84 -24.58 36.72
Cash and Cash Equivalent - Beginning of the 217.45 44.60 39.76 64.34 46.04
Year
Cash and Cash Equivalent - End of the Year 64.47 217.45 44.60 39.76 82.76
14
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
CAPITAL STRUCTURE
15
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
TECHNICAL CHARTS
16
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
FINANCIAL RATIOS
17
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
18
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
HUMAN RESOURCES
19
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
ANALYSIS
EBITDA
Absolute EBITDA saw a CAGR of 10.1% over the last 5 years, owing to contribution from
new businesses, improvement in the portfolio mix, new launches in North America partly
impacted by higher R&D investments in recent years. Strong growth momentum across key
markets coupled with margin expansion and cost reduction has resulted in ~80 bps
improvement in EBITDA on YoY basis.
Debt ratios
FY 15-16 had elevated Debt-Equity ratio of 0.32 and Debt – EBITDA ratio of 1.51 due to
acquisition of InvaGen & Exelan through debt fund. During the years, Cipla has managed to
lower the Debt- Equity ratio to 0.10 and Debt – EBITDA ratio to 0.50 generating strong
cashflow.
20
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
SHAREHOLDING PATTERN
Pledged 0 0 0 0
21
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
DIVIDEND SUMMARY
For the year ending March 2019 Cipla has declared an equity dividend of 150.00% amounting to
Rs 3 per share. At the current share price of Rs 572.20 this results in a dividend yield of 0.52%.
The company has a good dividend track report and has consistently declared dividends for the
last 5 years.
22
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
PEER COMPARISON
6 MONTHS COMPARISON
23
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
According to a recent survey, emergency care, anesthesia care, and pain management drugs
are the drugs which mostly get affected due to shortage.
The current situation might cause a shortage and increase in demands of certain medications
such as Hydroxychloroquine and Chloroquine, which are most talked about during these
pandemic times.
It is believed that the shortage might not occur for now as companies have stocks at least for
the next 5 months.
24
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
3.FDA Policies
The Covid impact, demand for drugs and the lockdown in various countries may force the
FDA to allow relaxation in a few areas:
• The review process of Generic medicine is lengthy, the demand and shortage created
may also force minor changes
• The Federal law requires the manufacturers to notify the FDA about shortages when
the circumstance arises. The rules do not apply to medical devices as it is
manufactured at multiple plants. The shortage of devices during the pandemic might
force the FDA to rethink on regulations on devices
• FDA might also rethink the number of inspections on the overseas manufacturing
plants
Example-To maximize the number of respirators available, FDA and CDC recently
announced that certain respirators regulated by CDC, but not by the FDA, can also be used.
4.Data & Analytics
Pharma industry has an enormous amount of data, which also brings in various challenges
• Integrating siloed data and derive insights
• Infrastructure to leverage the power of Big Data
• Leveraging unstructured data
• Advance insights from clinical trails
• Data privacy
• Social listening
The cost of drug development is skyrocketing, and the time taken for a drug to be launched is
also high. The industry has been using data for years, but the challenge lies in leveraging its
full potential. A large amount of clinical and molecular data available over the years can help
in predictive analytics, which can be used to hasten the process of clinical trials and drug
development.
Companies are leveraging data and analytics, but the current situation might want them to use
data even more efficiently for clinical trials, forecasting, and marketing. Infrastructure for big
data and social listening will also play a key role.
25
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
Almost 95% of the companies are using RWD or will be using it by 2021. Data accessibility
and security issues are a few of the challenges in using RWD, but it can be sorted out and will
gain more popularity as companies and the regulatory bodies from here on might look to
bring in innovative measures in clinical trials.
Clinical trials are gold dust for pharma but there are cases in the past where the drugs were
pulled out from the market even after FDA approval. The main problem with clinical trial is
it looks at a homogeneous population. To address this, FDA might relax the regulations on
RWD.
6.Digital Health
Digital health might be the next big thing as telemedicine / video consultations, health-related
videos and apps are gaining popularity.
Investment in online portals that help doctor-patient interaction will increase.
Example of gaining digital popularity
• Wellmind health (provides online courses for mindfulness-based cognitive therapy)
has seen a recent uptrend in the purchase and enquires
• Due to the current pandemic situation, hospitals in the UK have been instructed by
NHS England to increase telemedicine/video consultations
• Meditation apps Calm and Headspace have released free digital offerings to help
people cope up with panic and anxiety
7.Primary and Secondary Market
To control the drug shortages that occur often companies will reassess their strategies on the
primary and secondary market for manufacturing.
26
BHAKTI SHINDE- GURU NANAK INSTITUTE OF MANAGEMENT STUDIES
THANK YOU
27